Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares reached a new 52-week low during trading on Friday . The stock traded as low as $4.46 and last traded at $4.54, with a volume of 1,087,473 shares. The stock had previously closed at $4.60.

Several research firms have commented on ZIOP. Mizuho restated a “neutral” rating and set a $5.00 price objective (down from $7.00) on shares of Ziopharm Oncology in a report on Monday, July 18th. Griffin Securities reiterated a “buy” rating and issued a $21.00 price target on shares of Ziopharm Oncology in a report on Tuesday, June 7th. Raymond James Financial Inc. assumed coverage on Ziopharm Oncology in a report on Thursday, June 2nd. They issued a “market perform” rating on the stock. Vetr upgraded Ziopharm Oncology from a “buy” rating to a “strong-buy” rating and set a $9.76 price target on the stock in a report on Monday, April 25th. Finally, Zacks Investment Research upgraded Ziopharm Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $10.57.

The firm has a 50-day moving average of $5.88 and a 200 day moving average of $6.86. The firm’s market cap is $584.67 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.01. The company earned $1.97 million during the quarter, compared to analysts’ expectations of $1.89 million. The business’s revenue was up 623.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.69) EPS. Analysts predict that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current year.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. Swiss National Bank boosted its position in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares in the last quarter. California State Teachers Retirement System boosted its position in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares in the last quarter. California Public Employees Retirement System boosted its position in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares in the last quarter. Finally, Morgan Stanley boosted its position in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares in the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.